Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

This study tests whether adding targeted radiation to remaining cancer sites (local consolidative therapy) improves outcomes compared to continuing targeted drug therapy (TKI) alone in patients with metastatic non-small cell lung cancer (NSCLC) with 1–5 sites of spread. **You may be eligible if...** - You are 18 or older with confirmed NSCLC and a driver mutation (EGFR or ALK/ROS) - You have 1–5 sites of metastatic disease (fewer than 3 lesions per organ) - You have already received 2–4 months of TKI therapy without your cancer progressing - Your performance status is good (ECOG 0–2) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - Your cancer has progressed on TKI therapy - You have more than 5 metastatic sites, or 4 or more lesions in a single organ - You do not have a targetable driver mutation (EGFR or ALK/ROS) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.